Exosome Diagnostics, a company that has developed technology to test for disease by analyzing blood and other bodily fluids, has agreed to be acquired by Bio-Techne in a $250 million cash deal.
If Waltham, MA-based Exosome hits certain unspecified milestones, the company could receive up to $325 million more, the companies announced Monday after the market close. Bio-Techne (NASDAQ: TECH), based in Minneapolis, says it will finance the transaction with cash on hand and a revolving line of credit that it expects to obtain. The companies expect to close the deal by early August.
Exosome Diagnostics develops and sells diagnostics… Read more »
UNDERWRITERS AND PARTNERS